Celldex Therapeutics
Yahoo Finance • 6 months ago
Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Celldex Therapeutics (NASDAQ:CLDX) First Quarter 2024 Results Key Financial Results Net loss: US$32.8m (loss widened by 12% from 1Q 2023). US$0.56 loss per share. earnings-and-revenue-history All figures shown in the chart above are for... Full story
Yahoo Finance • 9 months ago
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Celldex Therapeutics, Inc. - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment ne... Full story
Yahoo Finance • 12 months ago
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th... Full story
Yahoo Finance • last year
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public of... Full story
Yahoo Finance • last year
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in a... Full story
Yahoo Finance • last year
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
-Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups- -Mean change from baseline to week 12 in UAS7 of -23.87 in 300 mg q8w dose g... Full story
Yahoo Finance • last year
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
- Response observed as early as week 1 and durable for up to 16 weeks - - Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications - - Phase 2 PN study to initiate in early 2024 -... Full story
Yahoo Finance • last year
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch - HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial resu... Full story
Yahoo Finance • last year
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an or... Full story
Yahoo Finance • last year
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 26th at 1:00... Full story
Yahoo Finance • last year
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of chronic sp... Full story
Yahoo Finance • last year
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in eosinophilic esophagitis (EoE... Full story
Yahoo Finance • last year
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape - - At week 24, 55% of all patients with CSU in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose... Full story
Yahoo Finance • 2 years ago
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
HAMPTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preclinical data from CDX-622, the Company’s bispecific antibody with dual targeting of the alarmin TSLP and stem cell factor (SCF),... Full story
Yahoo Finance • 2 years ago
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Phase 2 CSU enrollment completion expected in Q3 2023 - - Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 - - Phase 2 EoE study expected to initiate in June 2023 - HAMPTON, N.J., May... Full story
Yahoo Finance • 2 years ago
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%?
Key Insights Celldex Therapeutics' estimated fair value is US$54.52 based on 2 Stage Free Cash Flow to Equity Celldex Therapeutics is estimated to be 42% undervalued based on current share price of US$31.41 Our fair value estimate is 18%... Full story
Yahoo Finance • 2 years ago
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on... Full story
Yahoo Finance • 2 years ago
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
- Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 - HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported finan... Full story
Yahoo Finance • 2 years ago
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class addition to a historically limited treatment landscape - - At week 12, 56% of... Full story
Yahoo Finance • 2 years ago
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors. “We are pleased to welcome Dr. Jain to the Celldex Boar... Full story
